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Abstract 
Background: In recent years, the development and diagnosis of secondary cancer have become the primary 
concern of cancer survivors. A number of studies have been developing strategies to extract knowledge from 
the clinical data, aiming to identify important risk factors that can be used to prevent the recurrence of diseases. 
However, these studies do not focus on secondary cancer. Secondary cancer is lack of the strategies for clinical 
treatment as well as risk factor identification to prevent the occurrence. 
Methods: We propose an effective ensemble feature learning method to identify the risk factors for predicting 
secondary cancer by considering class imbalance and patient heterogeneity. We first divide the patients into 
some heterogeneous groups based on spectral clustering. In each group, we apply the oversampling method to 
balance the number of samples in each class and use them as training data for ensemble feature learning. The 
purpose of ensemble feature learning is to identify the risk factors and construct a diagnosis model for each 
group. The importance of risk factors is measured based on the properties of patients in each group separately. 
We predict secondary cancer by assigning the patient to a corresponding group and based on the diagnosis 
model in this corresponding group. 
Results: Analysis of the results shows that the decision tree obtains the best results for predicting secondary 
cancer in the three classifiers. The best results of the decision tree are 0.72 in terms of AUC when dividing the 
patients into 15 groups, 0.38 in terms of F1 score when dividing the patients into 20 groups. In terms of AUC, 
decision tree achieves 67.4% improvement compared to using all 20 predictor variables and 28.6% 
improvement compared to no group division. In terms of F1 score, decision tree achieves 216.7% improvement 
compared to using all 20 predictor variables and 80.9% improvement compared to no group division. Different 
groups provide different ranking results for the predictor variables. 
Conclusion: The accuracies of predicting secondary cancer using k-nearest neighbor, decision tree, support 
vector machine indeed increased after using the selected important risk factors as predictors. Group division 
on patients to predict secondary cancer on the separated models can further improve the prediction 
accuracies. The information discovered in the experiments can provide important references to the personality 
and clinical symptom representations on all phases of guide interventions, with the complexities of multiple 
symptoms associated with secondary cancer in all phases of the recurrent trajectory. 
Key words: secondary cancer, risk factors, class imbalance, patient heterogeneity, spectral clustering, ensemble 
learning 
Introduction 
Cancer has become the second leading cause of 
death globally, which is characterized as a 
heterogeneous disease consisting of many different 
subtypes [1-3]. From the report of the World Health 
Organization (WHO), there are an estimated 9.6 
million deaths due to cancer in 2018 [4]. Recently, the 
development and diagnosis of secondary cancer have 
become the main concern of cancer survivors [5-7]. In 
contrast to primary cancer which refers to initial 
cancer a person experiences, secondary cancer refers 
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to either metastasis from primary cancer, or different 
cancer unrelated to primary cancer [8]. Compared to 
people with the same age and gender who have never 
had cancer, cancer survivors have an increased chance 
of developing secondary cancer. It is important for 
cancer survivors to be aware of the risk factors for 
secondary cancers and maintain good follow-up 
health care [9-11]. Furthermore, the literature shows 
that secondary cancer should be predicted with 
regard to their personal risk factors and clinical 
symptoms [12-15].  
Over the years, many statistical methods have 
been developed to extract knowledge from the clinical 
data, to identify important risk factors that can be 
used to prevent the recurrence of diseases [16,17]. 
Tseng et al. [18] utilize five classification techniques to 
rank the importance of risk factors for diagnosing 
ovarian cancer. Liang et al. [19] combine five feature 
selection methods with support vector machine to 
develop predictive models for recurrence of 
hepatocellular carcinoma. However, the studies in 
[18] and [19] do not consider the class imbalance 
problem and the heterogeneity between patients. 
Similarly, for most existing studies, some do not deal 
with the class imbalance problem [18], some do not 
consider the heterogeneity between patients [20], and 
as far as we know, none focuses on secondary cancer. 
The presence of class imbalance is a problem in 
medical diagnosis, in which the abnormal instances 
are only a small percentage compared to a large 
number of normal ones. Especially for secondary 
cancer, class imbalance is an inevitable problem. For a 
dataset with class imbalance, machine learning 
methods are biased towards the majority class and the 
learned information are mostly from the normal 
instances, which lead to poor accuracy for identifying 
the rare abnormal instances. On the other hand, 
patient heterogeneity is also an important issue to 
consider. The diagnosis on the basis of data analysis 
results may not always suitable to a specific patient, 
given the biological variability among individuals 
[20,21].  In this study, we propose an effective ensemble 
feature learning method to identify the risk factors for 
predicting secondary cancer by considering class 
imbalance and patient heterogeneity. An 
oversampling method is utilized to deal with the class 
imbalance problem in secondary cancer. We divide 
the patients into some heterogeneous groups, and 
then identify the risk factors and construct a diagnosis 
model for each patient group for a more accurate 
prediction. To the best of our knowledge, this kind of 
methodology has never been proposed and applied 
for secondary cancer data analysis. 
Material and Methods 
Samples 
The dataset of samples we studied in this paper 
are provided by the Chung Shan Medical University 
Hospital, Jen-Ai Hospital, and Far Eastern Memorial 
Hospital. It mainly contains four types of cancers: 
breast cancer, maternal cancer, colorectal cancer, 
head, and neck cancer, where the percentage of 
secondary cancer patients are 1.7%, 1.8%, 3.6% and 
7.9%, respectively. Totally, 11380 patients have ever 
suffered from primary cancer, among which 458 (4%) 
patients suffered from secondary cancer. The two 
classes (no suffering from secondary cancer and 
suffering from secondary cancer) are highly 
unbalanced. We analyze the predictor variables to 
find what variables are associated with the risk factors 
for secondary cancer. The 20 predictor variables 
analyzed in this paper are based on the decision of the 
cancer expert committee, which is considered to be 
potentially relevant to secondary cancer. They include 
Age; Body Mass Index (BMI); 8 variables related to the 
status of cancer which are Primary Site (referred to the 
type of primary cancer), Histology, Behavior Code, 
Differentiation, Tumor Size, Pathologic Stage, 
Surgical Margin, Surgical; 7 variables related to 
radiological and chemical treatments which are 
Radiotherapy (RT), Radiotherapy (RT) surgery, 
Sequence of Local regional Therapy and Systemic 
Therapy, Dose to clinical target volumes (CTV)_High, 
Number to clinical target volumes (CTV)_High, Dose 
to clinical target volumes (CTV)_Low, Number to 
clinical target volumes (CTV)_Low; 3 variables related 
to lifestyle which are: Smoking, Betel Nut, Drinking. 
The analysis allows for a better understanding of 
which variables are more fundamental to secondary 
cancer. 
Method design 
Firstly, we divide the training data into some 
heterogeneous groups by using spectral clustering 
[22,23,24] and learn the training data in each group 
separately. In each group, we apply the Synthetic 
minority oversampling technique (SMOTE) [25] as the 
oversampling method to generate synthetic data in 
the minority class for class balance. Then, ensemble 
feature learning is performed to identify the risk 
factors and construct a diagnosis model for each 
group. In the testing process, each test data is first 
assigned to a group in the training dataset and then 
tested the result on the corresponding model. 
The procedure of ensemble feature learning 
mainly consists of four stages, as shown in Figure 1. 
(1) Rank the importance of predictor variables. 
We use 𝑡𝑡 -test to rank the importance of predictor 
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variables according to their 𝑝𝑝 values. Lower 𝑝𝑝-value 
denotes more importance. We set the weight of 
predictor variables based on the ranking results. For a 
predictor variable 𝑣𝑣 with rank order 𝑟𝑟, its weight is set 
as 𝑑𝑑 − 𝑟𝑟, where 𝑑𝑑 is the number of predictor variables.  
(2) Find out the unimportant predictor variables. 
We utilize three classifiers, i.e., k-nearest neighbor 
(kNN) [26], Decision Tree (DT) [27] and Support 
Vector Machine (SVM) [28], to classify the samples by 
increasing the predictor variables based on the 
ranking result. The predictor variables that do not 
increase the prediction accuracy are considered to be 
unimportant. The weights of unimportant predictor 
variables are set to 0.  
(3) Calculate the overall importance of predictor 
variables. For different classifiers, the unimportant 
predictor variables may be different. We calculate the 
overall importance of predictor variables as the 
average weight of using the three classifiers.  
(4) Select important predictor variables to 
construct a prediction model. We increase the number 
of predictor variables from 1 to 20 based on the overall 
importance in descending order. The combination of 
predictor variables obtaining the best prediction 
accuracy is selected for model construction. For 
example, if the three most important predictor 
variables obtain the best prediction accuracy, they will 
be selected for model construction. Beyond the 
prediction accuracy, we also consider the comments 
of clinical physicians. 
 
 
Figure 1. Procedure of ensemble feature learning 
 
Statistical analysis 
All statistical analyses are performed using 
Matlab 9.4.0 (R2018a) on Mac OS X 10.14.2 (18C54) 
with core i5 CPU and 8GB ram. We apply the AUC 
(Area Under Curve) [29] and 𝐹𝐹1 score [30] to evaluate 
the performance of the proposed method. AUC and 𝐹𝐹1 
score are two useful metrics for imbalanced datasets. 
AUC is the area under the curve of a ROC graph, 
which compares the Sensitivity vs (1-Specificity). Each 
point on the ROC curve represents a different choice 
for that true/false threshold. 𝐹𝐹1 score is a harmonic 
mean of precision and recall for a specific threshold. 
AUC evaluates a model independently of the choice 
of threshold, whereas 𝐹𝐹1  score is a measure for a 
particular model at a particular threshold. In general, 
AUC evaluates the test power (for best tests nearly 1). 
𝐹𝐹1 score evaluates how reliable a sensitive test is in the 
positive decision (nearly 1 for best tests).  
We use the toolbox of Matlab to run the three 
classifiers, i.e., kNN, DT and SVM. The spectral 
clustering algorithm is performed as the algorithm in 
[24]. The training data and test data are 80% and 20%, 
respectively. We create cross-validation partition for 
the dataset using Matlab function “cvpartition”. For 
SMOTE, the number of increased samples is ranged 
from 1 to 15 times of the samples in the minority class, 
the number of nearest neighbors is ranged from 3 to 
13, and the best result is recorded for the following 
steps. All experiments were repeated 10 times and the 
average results are reported.  
Results 
We apply the proposed method to learn the risk 
factors and predict secondary cancer. The number of 
divided groups is ranged from 1 to 20. Note that the 
number of divided groups being 1 is just the case that 
we apply ensemble feature learning without group 
division. The results of the prediction accuracies using 
the three classifiers, i.e., kNN, DT and SVM, are 
shown in Figure 2. Figure 2 shows the results in terms 
of AUC and 𝐹𝐹1 score, respectively. From the results, 
we can see that ensemble feature learning with group 
division performs better than ensemble feature 
learning without group division. DT obtains the best 
results in the three classifiers. The best results of DT 
are 0.72 in terms of AUC when dividing into 15 
groups, and 0.38 in terms of 𝐹𝐹1 score when dividing 
into 20 groups. The performance of DT shows an 
upward trend as the number of divided groups 
increases, while the performance improvements of 
kNN and SVM are not significant when dividing into 
more than 3 groups. 
Next, we show the ranking results based on the 
importance of the 20 predictor variables in the cases of 
with and without group division using the DT 
classifier. For the case of group division, we show the 
ranking results in each group when dividing into 5 
groups. The divided 5 groups are denoted as group 1, 
group 2, group 3, group 4, and group 5, respectively. 
As shown in Table 1, different groups provide 
different ranking results for the predictor variables. In 
the case of no group division, the top 5 important 
predictor variables are Primary Site, Pathologic Stage, 
Age, Surgical Margin, and Histology. In the case of 
group division, Primary Site, Pathologic Stage, and 
Surgical Margin are among the top 5 important 
predictor variables in each group. Age is among the 
top 3 important predictor variables in four groups. 
From the ranking results in Table 1, Primary Site, 
Pathologic Stage, Age, Surgical Margin are the four 
most critical risk factors in groups 2, 3, 5 and the case 
of no group division.  
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Figure 2. Results of the prediction accuracies using three classifiers 
 
Table 1. Ranking results of the importance in the 20 predictor variables for 4 types of cancers 
Rank 
 
No division 
 
5 Groups 
Group 1 Group 2 Group 3 Group 4 Group5 
1 Primary Site Pathologic Stage Surgical Margin Primary Site Primary Site Primary Site 
2 Pathologic Stage Primary Site Pathologic Stage' Pathologic Stage Pathologic Stage Pathologic Stage 
3 Age Surgical Margin Age Age Age Age 
4 Surgical Margin Surgical Primary Site Surgical Margin Smoking Surgical Margin 
5 Histology Histology Histology Smoking Surgical Margin Smoking 
6 Drinking Dose to clinical target 
volumes (CTV)_Low 
Surgical Number to clinical 
target volumes (CTV) 
_Low 
Drinking Drinking 
7 Betel Nut Number to clinical 
target volumes (CTV) 
_Low 
Number to clinical 
target volumes (CTV) 
_Low 
Histology Betel Nut Betel Nut 
8 Radiotherapy (RT) Age Betel Nut Drinking Number to clinical target 
volumes (CTV) _Low 
Histology 
9 Smoking Tumor Size Tumor Size Betel Nut Dose to clinical target 
volumes (CTV)_High 
Number to clinical 
target volumes (CTV) 
_Low 
10 Behavior Code Dose to clinical target 
volumes (CTV)_High 
Drinking Dose to clinical target 
volumes (CTV)_Low 
Histology Dose to clinical target 
volumes 
(CTV)_High 
11 Sequence of Local regional 
Therapy and Systemic 
Therapy 
Betel Nut Smoking Dose to clinical target 
volumes (CTV)_High 
Differentiation Differentiation 
12 Body Mass Index (BMI) Drinking Dose to clinical target 
volumes (CTV)_Low 
Surgical Number to clinical target 
volumes (CTV) _High 
Number to clinical 
target volumes (CTV) 
_High 
13 Number to clinical target 
volumes (CTV) _High 
Differentiation Dose to clinical target 
volumes (CTV)_High 
Tumor Size Surgical Surgical 
14 Differentiation Radiotherapy (RT) 
surgery 
Body Mass Index (BMI) Body Mass Index (BMI) Tumor Size Tumor Size 
15 Dose to clinical target 
volumes (CTV)_High 
Sequence of Local 
regional Therapy and 
Systemic Therapy 
Sequence of Local 
regional Therapy and 
Systemic Therapy 
Number to clinical 
target volumes (CTV) 
_High 
Body Mass Index (BMI) Body Mass Index 
(BMI) 
16 Dose to clinical target 
volumes (CTV)_Low 
Body Mass Index 
(BMI) 
Differentiation Differentiation Sequence of Local 
regional Therapy and 
Systemic Therapy 
Sequence of Local 
regional Therapy and 
Systemic Therapy 
17 Number to clinical target 
volumes (CTV) _Low 
Number to clinical 
target volumes (CTV) 
_High 
Radiotherapy (RT) 
surgery 
Sequence of Local 
regional Therapy and 
Systemic Therapy 
Dose to clinical target 
volumes (CTV)_Low 
Dose to clinical target 
volumes (CTV)_Low 
18 Radiotherapy (RT) surgery Smoking Radiotherapy (RT) Behavior Code Radiotherapy (RT) Radiotherapy (RT) 
19 Tumor Size Behavior Code Number to clinical 
target volumes (CTV) 
_High 
Radiotherapy (RT) 
surgery 
Behavior Code Behavior Code 
20 Surgical Radiotherapy (RT) Behavior Code Radiotherapy (RT) Radiotherapy (RT) 
surgery 
Radiotherapy (RT) 
surgery 
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We further investigate the performance in each 
group by varying the number of predictor variables. 
We show the results in Figure 3 with the same case in 
Table 1, i.e., dividing into 5 groups and no group 
division using DT classifier. In each group, we 
increase the number of predictor variables from 1 to 
20 based on their importance ranking results. Taking 
the no division case as an example, we first use 
Primary Site as the predictor variable and then use 
Primary Site and Pathologic Stage as the two 
predictor variables. For the no division case, the 
results do not change obviously as the number of 
predictor variables varies. For the case of dividing 
into 5 groups, in each group, the results change 
obviously as the number of predictor variables varies. 
Using a certain number of the important predictor 
variables, the results can be improved significantly. 
For the best results in terms of AUC, the number of 
predictor variables used in the no division case is 2, 
and the numbers of predictor variables used in the 
group division case are 17, 4, 8,16, 15, respectively. 
 
 
 
Figure 3. Results of the prediction accuracies by varying the number of predictor variables 
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Finally, to show the effectiveness of the 
proposed method, we also show the prediction results 
of the pure kNN, pure DT and pure SVM that are 
without ensemble feature learning. We compare the 
prediction results of the pure methods to that of the 
proposed method dividing into different numbers of 
groups, i.e., 1 group (no division), 5 groups, 10 
groups, 15 groups, and 20 groups. The comparison 
results in terms of AUC and 𝐹𝐹1 score are shown in 
Figures 4. From Figure 4, we can see that the 
accuracies of predicting secondary cancer using kNN, 
DT and SVM indeed increase after ensemble feature 
learning to select the important risk factors as the 
predictors. Group division to predict secondary 
cancer on the separated models can further improve 
the prediction accuracies. Note that the 𝐹𝐹1 score of the 
pure SVM is 0. After ensemble feature learning 
selecting the important risk factors as the predictors, 
the 𝐹𝐹1 score is improved to be larger than 0.22. DT 
obtains better results than kNN and SVM. The 
improvements by group division are more significant 
with the DT method. 
Discussion 
Whether or not a patient will have secondary 
cancer depends on many different things [18]. In this 
study, we learn the importance of 20 predictor 
variables related to secondary cancer for four types of 
cancer. To the best of our knowledge, this is the first 
study that utilizes machine learning methods to learn 
the risk factors and construct the prediction model for 
secondary cancer.  
Based on the data characteristics, i.e., class 
imbalance and patient heterogeneity, we use an 
oversampling method to increase the samples in the 
minority class and use spectral clustering to divide 
the samples into some groups. Spectral clustering is 
an efficient clustering algorithm, with the 
performance being superior to that of traditional 
clustering methods, such as K-means. Compared to no 
group division in which all patients using only one 
diagnosis model, group division constructs separated 
diagnosis models for the patients in different groups. 
The patients in a group are more similar than the 
patients in other groups, and they use a diagnosis 
model. Thus, using the models constructed from the 
groups has higher precision accuracy than using the 
model constructed from all samples. That is the 
reason why group division can improve the accuracy 
of predicting secondary cancer. 
Since for different types of cancers, the ranking 
results for the predictor variables are different. We 
also show the ranking results of the importance in the 
19 predictor variables (excluding the predictor 
variable of Primary Site) for each type of cancer. 
Similar to Table 1, Tables 2, 3, 4 and 5 show the 
ranking results for the four types of cancers, 
respectively. In no group division case, Age, 
Pathologic Stage, and Surgical Margin are the three 
most critical risk factors for maternal cancer, 
colorectal cancer, head, and neck cancer. For breast 
cancer, Pathologic Stage, Histology and Surgical 
Margin are the three most critical risk factors in no 
group division case. In the group division case, 
different groups provide different ranking results for 
the predictor variables. For colorectal cancer, head 
and neck cancer, Age, Pathologic Stage, and Surgical 
Margin are the three most critical risk factors in no 
group division case and remain in the five most 
critical risk factors in group division case. For breast 
cancer and maternal cancer, some important predictor 
variables in no group division case do not remain the 
same level of importance in group division case, e.g., 
in Table 3, age is the most critical risk factor in no 
group division case, however age is ranked 12 in 
Group 1 in group division case. One of the reasons is 
that the patients have similar ages. Another reason is 
that the number of patients suffering from secondary 
cancer is only 3. To obtain more samples suffering 
from secondary cancer to train the diagnosis models, 
we analyze the four types of cancers together in the 
experiments. 
 
 
Figure 4. Comparison of the prediction accuracies 
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Table 2. Ranking results of the importance in the 19 predictor variables for breast cancer 
Rank No division 
 
5 Groups 
Group 1 Group 2 Group 3 Group 4 Group5 
1 Pathologic Stage Number to clinical target 
volumes (CTV) _High 
Surgical Margin Surgical Margin Surgical Margin Surgical Margin 
2 Histology Dose to clinical target 
volumes (CTV)_Low 
Pathologic Stage Histology Smoking Smoking 
3 Surgical Margin Number to clinical target 
volumes (CTV) _Low 
Number to clinical target 
volumes (CTV) _High 
Pathologic Stage Histology Pathologic Stage 
4 Body Mass Index 
(BMI) 
Pathologic Stage Dose to clinical target 
volumes (CTV)_Low 
Number to clinical 
target volumes (CTV) 
_High 
Number to clinical 
target volumes 
(CTV) _High 
Histology 
5 Age Dose to clinical target 
volumes (CTV)_High 
Body Mass Index (BMI) Dose to clinical target 
volumes (CTV)_Low 
Dose to clinical 
target volumes 
(CTV)_Low 
Number to clinical target 
volumes (CTV) _High 
6 Number to clinical 
target volumes (CTV) 
_High 
Age Number to clinical target 
volumes (CTV) _Low 
Number to clinical 
target volumes (CTV) 
_Low 
Pathologic Stage Body Mass Index (BMI) 
7 Betel Nut Body Mass Index (BMI) Age Smoking Number to clinical 
target volumes 
(CTV) _Low 
Betel Nut 
8 Dose to clinical target 
volumes (CTV)_Low 
Surgical Margin Dose to clinical target 
volumes (CTV)_High 
Body Mass Index (BMI) Body Mass Index 
(BMI) 
Drinking 
9 Behavior Code Surgical Tumor Size Age Betel Nut Dose to clinical target 
volumes (CTV)_Low 
10 Number to clinical 
target volumes (CTV) 
_Low 
Tumor Size Betel Nut Betel Nut Surgical Number to clinical target 
volumes (CTV) _Low 
11 Dose to clinical target 
volumes 
(CTV)_High 
Histology Differentiation Dose to clinical target 
volumes (CTV)_High 
Dose to clinical 
target volumes 
(CTV)_High 
Surgical 
12 Tumor Size Betel Nut Surgical Surgical Drinking Dose to clinical target 
volumes (CTV)_High 
13 Differentiation Differentiation Histology Drinking Age Age 
14 Drinking Radiotherapy (RT) Radiotherapy (RT) Differentiation Radiotherapy (RT) Differentiation 
15 Smoking Smoking Drinking Tumor Size Tumor Size Tumor Size 
16 Radiotherapy (RT) Drinking Smoking Radiotherapy (RT) Differentiation Radiotherapy (RT) 
17 Sequence of Local 
regional Therapy and 
Systemic Therapy 
Sequence of Local 
regional Therapy and 
Systemic Therapy 
Sequence of Local 
regional Therapy and 
Systemic Therapy 
Radiotherapy (RT) 
surgery 
Radiotherapy (RT) 
surgery 
Sequence of Local regional 
Therapy and Systemic 
Therapy 
18 Radiotherapy (RT) 
surgery 
Behavior Code Behavior Code Sequence of Local 
regional Therapy and 
Systemic Therapy 
Sequence of Local 
regional Therapy 
and Systemic 
Therapy 
Behavior Code 
19 Surgical Radiotherapy (RT) 
surgery 
Radiotherapy (RT) 
surgery 
Behavior Code Behavior Code Radiotherapy (RT) surgery 
 
 
Limitations and futures studies 
Since there is no existing study using machine 
learning methods to predict secondary cancer, we 
have no idea about which kind of machine learning 
methods are the most suitable. In this study, we try 
some widely used classification methods for 
secondary cancer prediction, i.e., k-nearest neighbor 
(kNN), Linear Discriminant Analysis (LDA), 
Quadratic Discriminant Analysis (QDA), Decision 
Tree (DT) and Support Vector Machine (SVM), and 
Naïve Bayes. kNN, DT and SVM obtain better results 
than other methods. Thus, we apply kNN, DT and 
SVM in our method for ensemble learning. From the 
results, we find that DT has better performance than 
the other two classifiers. That may be because DT uses 
a tree-like model of decisions, which has similar 
consideration of group division. Therefore, group 
division can future improves the performance of DT, 
especially when the number of divided groups 
increases. We just try the division of 20 groups, we do 
not know if increasing the number of divided groups 
can further improve the performance. In the future, 
we will try more methods to predict secondary cancer 
and investigate the optimal number of division 
groups. 
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Table 3. Ranking results of the importance in the 19 predictor variables for maternal cancer 
Rank No division 
 
5 Groups 
Group 1 Group 2 Group 3 Group 4 Group5 
1 Age Surgical Margin Surgical Margin Surgical Margin Surgical Margin Pathologic Stage 
2 Pathologic Stage Smoking Smoking Smoking Pathologic Stage Surgical Margin 
3 Surgical Margin Pathologic Stage Pathologic Stage Pathologic Stage Drinking Drinking 
4 Body Mass Index (BMI) Histology Age Drinking Sequence of Local 
regional Therapy and 
Systemic Therapy 
Age 
5 Histology Body Mass Index (BMI) Histology Age Age Sequence of Local 
regional Therapy and 
Systemic Therapy 
6 Betel Nut Drinking Body Mass Index (BMI) Histology Smoking Smoking 
7 Number to clinical 
target volumes (CTV) 
_High 
Betel Nut Sequence of Local 
regional Therapy and 
Systemic Therapy 
Sequence of Local 
regional Therapy and 
Systemic Therapy 
Histology Histology 
8 Dose to clinical target 
volumes (CTV)_Low 
Number to clinical 
target volumes (CTV) 
_High 
Betel Nut Body Mass Index (BMI) Number to clinical 
target volumes (CTV) 
_High 
Body Mass Index (BMI) 
9 Number to clinical 
target volumes (CTV) 
_Low 
Sequence of Local 
regional Therapy and 
Systemic Therapy 
Dose to clinical target 
volumes (CTV)_Low 
Number to clinical 
target volumes (CTV) 
_High 
Dose to clinical target 
volumes (CTV)_Low 
Betel Nut 
10 Smoking Differentiation Drinking Dose to clinical target 
volumes (CTV)_Low 
Number to clinical 
target volumes (CTV) 
_Low 
Number to clinical 
target volumes (CTV) 
_High 
11 Differentiation Dose to clinical target 
volumes (CTV)_Low 
Number to clinical 
target volumes (CTV) 
_High 
Betel Nut Body Mass Index (BMI) Dose to clinical target 
volumes (CTV)_Low 
12 Radiotherapy (RT) 
surgery 
Age Differentiation Surgical Differentiation Differentiation 
13 Behavior Code Surgical Number to clinical 
target volumes (CTV) 
_Low 
Number to clinical 
target volumes (CTV) 
_Low 
Surgical Number to clinical 
target volumes (CTV) 
_Low 
14 Radiotherapy (RT) Number to clinical 
target volumes (CTV) 
_Low 
Surgical Radiotherapy (RT) Betel Nut Surgical 
15 Drinking Dose to clinical target 
volumes (CTV)_High 
Radiotherapy (RT) Differentiation Radiotherapy (RT) Radiotherapy (RT) 
16 Tumor Size Tumor Size Dose to clinical target 
volumes (CTV)_High 
Dose to clinical target 
volumes (CTV)_High 
Dose to clinical target 
volumes (CTV)_High 
Dose to clinical target 
volumes (CTV)_High 
17 Dose to clinical target 
volumes (CTV)_High 
Radiotherapy (RT) Tumor Size Tumor Size Tumor Size Tumor Size 
18 Sequence of Local 
regional Therapy and 
Systemic Therapy 
Behavior Code Behavior Code Behavior Code Behavior Code Behavior Code 
19 Surgical Radiotherapy (RT) 
surgery 
Radiotherapy (RT) 
surgery 
Radiotherapy (RT) 
surgery 
Radiotherapy (RT) 
surgery 
Radiotherapy (RT) 
surgery 
 
On the other hand, from the dataset, we learn the 
types of original cancer and which patient has 
secondary cancer. However, we do not learn about the 
types of secondary cancer. Learning the types of 
secondary cancer is useful for therapeutics and 
preventive [31]. This is also one of the future research 
directions of this study.  
Conclusion 
The present study shows a proposed method 
using ensemble feature learning to identify the risk 
factors for predicting secondary cancer by considering 
class imbalance and patient heterogeneity. In the 
proposed method, we divide the training data into 
some heterogeneous groups and construct a diagnosis 
model for each group for a more accurate prediction. 
Analysis of the results shows that the accuracies of 
predicting secondary cancer indeed increased after 
using the selected important risk factors as predictors. 
Group division to predict secondary cancer on the 
separated models can further improve the prediction 
accuracies. Our results can provide important 
references to the personality and clinical symptom 
representations on all phases of guide interventions, 
with the complexities of multiple symptoms 
associated with secondary cancer in all phases of the 
recurrent trajectory. 
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Table 4. Ranking results of the importance in the 19 predictor variables for colorectal cancer 
Rank No division 
 
5 Groups 
Group 1 Group 2 Group 3 Group 4 Group5 
1 Age Pathologic Stage Pathologic Stage Pathologic Stage Pathologic Stage Pathologic Stage 
2 Pathologic Stage Surgical Margin Surgical Margin Surgical Margin Surgical Margin Age 
3 Surgical Margin Smoking Smoking Age Age Surgical Margin 
4 Betel Nut Drinking Drinking Smoking Smoking Smoking 
5 Histology Age Age Drinking Drinking Drinking 
6 Dose to clinical 
target volumes 
(CTV)_Low 
Sequence of Local 
regional Therapy and 
Systemic Therapy 
Sequence of Local 
regional Therapy and 
Systemic Therapy 
Sequence of Local 
regional Therapy and 
Systemic Therapy 
Sequence of Local regional 
Therapy and Systemic 
Therapy 
Sequence of Local regional 
Therapy and Systemic 
Therapy 
7 Number to clinical 
target volumes 
(CTV) _High 
Body Mass Index 
(BMI) 
Body Mass Index 
(BMI) 
Betel Nut Betel Nut Body Mass Index (BMI) 
8 Body Mass Index 
(BMI) 
Betel Nut Betel Nut Number to clinical target 
volumes (CTV) _Low 
Body Mass Index (BMI) Betel Nut 
9 Radiotherapy (RT) Histology Histology Body Mass Index (BMI) Number to clinical target 
volumes (CTV) _Low 
Number to clinical target 
volumes (CTV) _Low 
10 Smoking Number to clinical 
target volumes (CTV) 
_Low 
Number to clinical 
target volumes (CTV) 
_Low 
Histology Histology Dose to clinical target 
volumes (CTV)_Low 
11 Drinking Dose to clinical target 
volumes (CTV)_Low 
Differentiation Dose to clinical target 
volumes (CTV)_Low 
Differentiation Histology 
12 Number to clinical 
target volumes 
(CTV) _Low 
Number to clinical 
target volumes (CTV) 
_High 
Number to clinical 
target volumes (CTV) 
_High 
Differentiation Tumor Size Number to clinical target 
volumes (CTV) _High 
13 Dose to clinical 
target volumes 
(CTV)_High 
Surgical Dose to clinical target 
volumes (CTV)_Low 
Number to clinical target 
volumes (CTV) _High 
Dose to clinical target 
volumes (CTV)_Low 
Differentiation 
14 Radiotherapy (RT) 
surgery 
Differentiation Surgical Radiotherapy (RT) Radiotherapy (RT) Tumor Size 
15 Differentiation Radiotherapy (RT) Radiotherapy (RT) Tumor Size Number to clinical target 
volumes (CTV) _High 
Surgical 
16 Behavior Code Dose to clinical target 
volumes (CTV)_High 
Tumor Size Surgical Surgical Radiotherapy (RT) 
17 Tumor Size Tumor Size Dose to clinical target 
volumes 
(CTV)_High 
Dose to clinical target 
volumes (CTV)_High 
Dose to clinical target 
volumes (CTV)_High 
Dose to clinical target 
volumes (CTV)_High 
18 Sequence of Local 
regional Therapy 
and Systemic 
Therapy 
Radiotherapy (RT) 
surgery 
Radiotherapy (RT) 
surgery 
Behavior Code Behavior Code Behavior Code 
19 Surgical Behavior Code Behavior Code Radiotherapy (RT) 
surgery 
Radiotherapy (RT) surgery Radiotherapy (RT) surgery 
 
Table 5. Ranking results of the importance in the 19 predictor variables for head and neck cancer 
Rank 
 
No division 
 
5 Groups 
Group 1 Group 2 Group 3 Group 4 Group5 
1 Age Pathologic Stage Age Pathologic Stage Age Pathologic Stage 
2 Pathologic Stage Age Pathologic Stage Age Pathologic Stage Age 
3 Surgical Margin Surgical Margin Surgical Margin Surgical Margin Surgical Margin Surgical Margin 
4 Dose to clinical target 
volumes (CTV)_Low 
Smoking Smoking Smoking Smoking Drinking 
5 Histology Drinking Drinking Drinking Body Mass Index (BMI) Smoking 
6 Betel Nut Body Mass Index (BMI) Body Mass Index (BMI) Body Mass Index (BMI) Drinking Body Mass Index (BMI) 
7 Body Mass Index 
(BMI) 
Betel Nut Sequence of Local 
regional Therapy and 
Systemic Therapy 
Sequence of Local 
regional Therapy and 
Systemic Therapy 
Sequence of Local 
regional Therapy and 
Systemic Therapy 
Sequence of Local 
regional Therapy and 
Systemic Therapy 
8 Number to clinical 
target volumes (CTV) 
_Low 
Sequence of Local 
regional Therapy and 
Systemic Therapy 
Betel Nut Betel Nut Number to clinical target 
volumes (CTV) _Low 
Betel Nut 
9 Number to clinical 
target volumes (CTV) 
_High 
Number to clinical 
target volumes (CTV) 
_Low 
Histology Number to clinical target 
volumes (CTV) _Low 
Dose to clinical target 
volumes (CTV) _Low 
Number to clinical 
target volumes (CTV) 
_Low 
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Rank 
 
No division 
 
5 Groups 
Group 1 Group 2 Group 3 Group 4 Group5 
10 Drinking Histology Number to clinical 
target volumes (CTV) 
_Low 
Tumor Size Betel Nut Dose to clinical target 
volumes (CTV) _Low 
11 Differentiation Dose to clinical target 
volumes (CTV) _Low 
Dose to clinical target 
volumes (CTV) _Low 
Histology Histology Histology 
12 Dose to clinical target 
volumes (CTV)_High 
Number to clinical 
target volumes (CTV) 
_High 
Radiotherapy (RT) Dose to clinical target 
volumes (CTV) _Low 
Tumor Size Tumor Size 
13 Smoking Radiotherapy (RT) Differentiation Radiotherapy (RT) Differentiation Differentiation 
14 Radiotherapy (RT) Surgical Number to clinical 
target volumes (CTV) 
_High 
Differentiation Number to clinical target 
volumes (CTV) _High 
Number to clinical 
target volumes (CTV) 
_High 
15 Radiotherapy (RT) 
surgery 
Differentiation Surgical Number to clinical target 
volumes (CTV) _High 
Dose to clinical target 
volumes (CTV) _High 
Dose to clinical target 
volumes (CTV) _High 
16 Behavior Code Tumor Size Tumor Size Surgical Radiotherapy (RT) Radiotherapy (RT) 
17 Sequence of Local 
regional Therapy and 
Systemic Therapy 
Dose to clinical target 
volumes (CTV) _High 
Dose to clinical target 
volumes (CTV) _High 
Dose to clinical target 
volumes (CTV) _High 
Surgical Surgical 
18 Tumor Size Behavior Code Behavior Code Behavior Code Behavior Code Behavior Code 
19 Surgical Radiotherapy (RT) 
surgery 
Radiotherapy (RT) 
surgery 
Radiotherapy (RT) 
surgery 
Radiotherapy (RT) 
surgery 
Radiotherapy (RT) 
surgery 
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